Business Description
Invivyd Inc
NAICS : 325412
SIC : 2834
ISIN : US00534A1025
Description
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 100.92 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.12 | |||||
| 9-Day RSI | 34.51 | |||||
| 14-Day RSI | 41.87 | |||||
| 6-1 Month Momentum % | 17.61 | |||||
| 12-1 Month Momentum % | -48.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.54 | |||||
| Quick Ratio | 9.54 | |||||
| Cash Ratio | 9.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.54 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -49.87 | |||||
| ROA % | -44.73 | |||||
| ROIC % | -1702.81 | |||||
| ROC (Joel Greenblatt) % | -3648.59 | |||||
| ROCE % | -46.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 0.63 | |||||
| EV-to-EBIT | 0.68 | |||||
| EV-to-EBITDA | 0.69 | |||||
| EV-to-FCF | 0.62 | |||||
| Price-to-Net-Current-Asset-Value | 0.65 | |||||
| Price-to-Net-Cash | 0.68 | |||||
| Earnings Yield (Greenblatt) % | 147.06 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IVVD
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Invivyd Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.61 | ||
| Beta | 0 | ||
| Volatility % | 136.38 | ||
| 14-Day RSI | 41.87 | ||
| 14-Day ATR ($) | 0.112301 | ||
| 20-Day SMA ($) | 1.793 | ||
| 12-1 Month Momentum % | -48.93 | ||
| 52-Week Range ($) | 0.9802 - 4.09 | ||
| Shares Outstanding (Mil) | 109.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Invivyd Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Invivyd Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Invivyd Inc Frequently Asked Questions
What is Invivyd Inc(IVVD)'s stock price today?
The current price of IVVD is $1.63. The 52 week high of IVVD is $4.09 and 52 week low is $0.98.
When is next earnings date of Invivyd Inc(IVVD)?
The next earnings date of Invivyd Inc(IVVD) is 2023-11-10 Est..
Does Invivyd Inc(IVVD) pay dividends? If so, how much?
Invivyd Inc(IVVD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers